Association of histone modification enzyme in the progression of castrate resistant prostate cancer

2016 Fiscal Year Final Research Report

• Project/Area Number: 15K15585
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Urology
• Research Institution: Kyoto Prefectural University of Medicine
• Principal Investigator: SHIRAISHI TAKUMI 京都府立医科大学, 医学(系)研究科(研究院), 客員講師 (70405314)
• Project Period (FY): 2015-04-01 – 2017-03-31
• Keywords: 去勢抵抗性前立腺癌 / アンドロゲン除去療法 / ヒストン修飾酵素 / JARID1B / microRNA-29a

Outline of Final Research Achievements

We demonstrated that JARID1B was induced under androgen depleted condition. JARID1B was up-regulated in cancer specimens, especially in metastatic cancer tissues from prostate cancer patients compared to normal prostate tissues. JARID1B knockdown increased 3meH3K4 and decrease cell proliferation in LNCaP cells. Furthermore, expression of JARID1B was controlled by microRNA-29a through two sites of 3’UTR region. These results suggest the possibility that JARID1B is associated with the survival of prostate cancer cells under androgen depleted condition. Further study is ongoing to evaluate the direct association of JARID1B with the development of castrate resistant prostate cancer under androgen depleted condition.

Free Research Field

泌尿器科学